Claims:

1. A substituted 4-, 5-, 6-, or 7-indole or indoline derivative of Formula



(I)

wherein W is N, C, CH or COH and the dotted lines indicate optional bonds and

wherein A is a group having the formula



(IIA)

wherein X is CR^{1A}, CHR^{1A}, N, NR^{1B}, O, or S. where R^{1A} is as defined for R^3 to R^9 below, and where R^{1B} is as defined for R^{10} below;

Y is CR^{2A}, CHR^{2A}, N, NR^{2B}, O, or S, where R^{2A} is as defined for R^3 to R^9 below and where R^{2B} is as defined for R^{10} below, and

the dotted lines indicate optional bonds;

provided that X and Y are not both O or S;

A is a group having the formula



(IIB)

wherein X is CR^{1A}, CHR^{1A}, N, NR^{1B}, O, or S, where R^{1A} is as defined for R^3 to R^9 below, and where R^{1B} is as defined for R^{10} below;

U is C, CH, or N; and

the dotted lines indicate optional bonds; or

A is a group having the formula



(IIC)

wherein U is C, CH, or N;

Y is CR^{2A}, CHR^{2A}, N, NR^{2B}, O, or S, where R^{2A} is as defined for R^3 to R^9 below and where R^{2B} is as defined for R^{10} below; and

the dotted lines indicate optional bonds;

n is 0, 1, 2, 3, 4, or 5, and m is 0, 1, 2, 3, 4, or 5;

Z is CH_2, O, S, CO, SO, or SO_2, provided that if n is 0 then Z is CH_2;

R^3-R^9 and R^{11} to R^{12} are independently selected from hydrogen, halogen, cyano, nitro, C_{1-6}-alk(en/yn)yl, C_{1-6} alkoxy, C_{1-6}-alkylthio, hydroxy, hydroxy-C_{1-6}-alkyl, C_{1-6}-alkoxycarbonyl, C_{3-8}-cycloalk(en)yl, C_{3-8}-cycloalk(en)yl-C_{1-6}-alk(en/yn)yl, C_{1-6}-alkylcarbonyl, phenylcarbonyl, halogen substituted phenylcarbonyl, trifluoromethyl, trifluoromethylsulfonyloxy, C_{1-6} alkylsulfonyl, aryl and heteroaryl, and/or two adjacent groups taken from R^3 - R^9 may together form a methylenedioxy group,
and/or two adjacent groups R^7 - R^9 may together form a cyclopentyl or cyclohexyl ring which may be substituted with one or more methyl groups,
and/or one of R^3-R^9 may alternatively be a group -$NR^{13}R^{14}$ wherein R^{13} is as defined for R^{10} below and R^{14} is hydrogen, C_{1-6}-alk(en/yn)yl, C_{3-8}-cycloalk(en)yl, C_{3-8}-cycloalk(en)yl-C_{1-6} alk(en/yn)yl, aryl, heteroaryl, aryl-C_{1-6} alkyl, or heteroaryl-C_{1-6}-alkyl;

R^{10} is

- hydrogen, C_{1-6}-alk(en/yn)yl, C_{3-8}-cycloalk(en)yl, C_{3-8}-cycloalk(en)yl-C_{1-6}-alk(en/yn)yl, aryl, heteroaryl, aryl-C_{1-6}-alkyl, heteroaryl-C_{1-6}-alkyl, acyl, thioacyl, C_{1-6}-alkylsulfonyl, trifluoromethylsulfonyl, arylsulfonyl, or heteroarylsulfonyl;
- $R^{15}VCO$- wherein V is O or S and R^{15} is C_{1-6}-alk(en/yn)yl, C_{3-8}-cycloalk(en)yl, C_{3-8}-cycloalk(en)yl-C_{1-6}-alk(en/yn)yl, aryl, or heteroaryl; or
- a group $R^{16}R^{17}NCO$- or $R^{16}R^{17}NCS$- wherein R^{16} and R^{17} are independently selected from hydrogen, C_{1-6}-alk(en/yn)yl, C_{3-8}-cycloalk(en)yl, C_{3-8}-cycloalk(en)yl-C_{1-6}-alk(en/yn)yl, heteroaryl, or aryl, or R^{16} and R^{17} together with the N-atom to which they are linked, form a pyrrolidinyl, piperidinyl, morpholinyl, or perhydroazepin group;

or an acid addition salt thereof.

2. A compound according to claim 1 wherein A is a group having the formula



(IIA)

wherein X, Y, the dotted lines and R^3- R^6 are as defined in claim 1.

3. A compound according to claim 2 wherein A is a group having the formula



wherein R^3 to R^6 and the dotted lines are as defined in claim 2.

4. A compound according to claim 3 wherein A is a group having the formula



or

wherein R^3 to R^6 and the dotted lines are as defined in claim 3.

5. A compound according to claim 1 having the formula



(II)

wherein R^7 to R^{12}, W, A, Z , n, m and the dotted lines are as defined in claim 1.

6. A compound according to claims 1 to 5 wherein Z is CH_2 and n + m is 0, 1, 2, 3, 4, 5, or 6.

7. A compound according to claim 1-6 wherein W is N.

8. A compound according to claim 1 having the formula



(II)

wherein R^7 to R^{12}, W, Z , n, m and the dotted lines are as defined in claim 1 and A is a group having the formula



(IIA)

wherein X, Y, the dotted lines and R^3-R^6 is as defined in claim 1.

9. A compound according to claim 8 wherein A is a group having the formula



wherein R^3 to R^6 and the dotted line is as defined in claim 8.

10. A compound according to claim 9 wherein A is a group having the formula





or



wherein R^3 to R^6 and the dotted line is as defined in claim 9.

11. A compound of claims 1-10 wherein Z is CH_2 and n + m is 0, 1, 2, 3, 4, 5, or 6 and R^3-R^9 and R^{11}-R^{12} is hydrogen, halogen, cyano, nitro, C_{1-6}-alkyl, C_{1-6}-alkoxy hydroxy, hydroxy-C_{1-6}-alkyl, C_{1-6}-alkoxycarbonyl and trifluoromethyl; and R^{10} is hydrogen.

12. A compound according to claim 8 -11 wherein W is N.

13. A compound according to claim 1 which is

1-(2-(3-Benzofuranyl)ethyl)-4-(1H-indol-4-yl)piperazine,

1-(3-Benzofuranylmethyl)-4-(1H-indol-4-yl)piperazine,

1-(2-(5-Fluoro-3-benzofuranyl)ethyl)-4-(1H-indol-4-yl)piperazine,

1-(4-(5-Fluoro-3-benzofuranyl)-1-butyl)-4-(1H-indol-4-yl)piperazine,

1-(2-(1H-Indol-3-yl)ethyl)-4-(1H-indol-4-yl)piperazine,

1-(3-(1H-Indol-3-yl)-1-propyl)-4-(1H-indol-4-yl)piperazine,

1-(4-(1H-Indol-3-yl)-1-butyl)-4-(1H-indol-4-yl)piperazine,

1-(3-(5-Fluoro-3-benzofuranyl)-1-propyl)-4-(1H-indol-4-yl)piperazine,

1-(2-(2-Methyl-4,5,6,7-tetrafluoro-3-benzofuranyl)ethyl)-4-(1H-indol-4-yl)piperazine,

1-(2-(3-Indazolyl)ethyl)-4-(1H-indol-4-yl)piperazine,

1-(2-(6-Chloro-3-indazolyl)ethyl)-4-(1H-indol-4-yl)piperazine,

1-(2-(7-Cyano-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)piperazine,

1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)piperazine,

1-(2-(4-Chloro-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)piperazine,

1-(2-(5-Fluoro-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)piperazine,

1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)-1,2,3,6-tetrahydropyridine,

1-(2-(5-Fluoro-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)-1,2,3,6-tetrahydropyridine,

1-(2-(7-Bromo-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)piperazine,

1-(1-Allyl-1H-indol-4-yl)-4-(2-(6-chloro-1H-indol-3-yl)ethyl)piperazine,

1-(1-Allyl-1H-indol-4-yl)-4-(2-(5-fluoro-1H-indol-3-yl)ethyl)piperazine,

1-(1-Benzyl-1H-indol-4-yl)-4-(2-(6-chloro-1H-indol-3-yl)ethyl)piperazine,

1-(1-Benzyl-1H-indol-4-yl)-4-(2-(5-fluoro-1H-indol-3-yl)ethyl)piperazine,

1-(1-Benzyl-1H-indol-4-yl)-4-(2-(5-bromo-1H-indol-3-yl)ethyl)piperazine,

1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(1-propargyl-1H-indol-4-yl)piperazine,

1-(2-(1H-Indol-3-yl)ethyl)-4-(1-propargyl-1H-indol-4-yl)piperazine,

1-(2-(5-Fluoro-1H-indol-3-yl)ethyl)-4-(1-propargyl-1H-indol-4-yl)piperazine,

1-(2-(5-Bromo-1H-indol-3-yl)ethyl)-4-(1-propargyl-1H-indol-4-yl)piperazine,

1-(1-Benzyl-1H-indol-4-yl)-4-(2-(1H-indol-3-yl)ethyl)piperazine,

1-(2-(5-Bromo-1H-indol-3-yl)ethyl)-4-(1H-indol-5-yl)piperazine,

1-(2-(5-Chloro-1H-indol-3-yl)ethyl)-4-(1H-indol-5-yl)piperazine,

1-(2-(5-Fluoro-1H-indol-3-yl)ethyl)-4-(6-hydroxymethyl-1H-indol-4-yl)piperazine,

1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(6-hydroxymethyl-1H-indol-4-yl)piperazine,

1-(2-(5-Bromo-1H-indol-3-yl)ethyl)-4-(6-hydroxymethyl-1H-indol-4-yl)piperazine,

1-(3-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-propyl)-4-(1H-indol-4-yl)piperazine,

1-(2-(1H-Indol-3-yl)ethyl)-4-(6-methoxycarbonyl-1H-indol-4-yl)piperazine,

1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(6-methoxycarbonyl-1H-indol-4-yl)piperazine,

1-(2-(5-Fluoro-3-benzofuranyl)ethyl)-4-(6-methoxycarbonyl-1H-indol-4-yl)piperazine,

1-(5-Fluoro-3-benzofuranylmethyl)-4-(1H-indol-4-yl)piperazine,

1-(3-Cyano-1H-indol-4-yl)-4-(2-(1H-indol-3-yl)ethyl)piperazine,

1-(3-Cyano-1H-indol-4-yl)-4-(2-(5-fluoro-3-benzofuranyl)ethyl)piperazine,

1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(3-cyano-1H-indol-4-yl)piperazine,

1-(2-(3-Benzofuranyl)ethyl)-4-(3-cyano-1H-indol-4-yl)piperazine,

1-(1H-Indol-4-yl)-4-(2-(5-methyl-3-benzofuranyl)ethyl)piperazine,

1-(1H-Indol-4-yl)-4-(2-(4-methyl-3-benzofuranyl)ethyl)piperazine,

1-(3-(5-Fluoro-3-benzofuranyl)-1-propyl)-4-(1H-indol-4-yl)-1,2,3,6-tetrahydropyridine,

1-(2-(5-Chloro-3-benzofuranyl)ethyl)-4-(1H-indol-4-yl)piperazine,

1-(1H-Indol-4-yl)-4-(2-(6-methyl-3-benzofuranyl)ethyl)piperazine,

1-(2-(7-Chloro-3-benzofuranyl)ethyl)-4-(1H-indol-4-yl)piperazine,

1-(2-(4-Chloro-1H-indol-3-yl)ethyl)-4-(3-cyano-1H-indol-4-yl)piperazine,

1-(2-(6-Chloro-1H-indol-3-yl)-4-(1H-indol-4-yl)piperidine,

1-(2-(5-Chloro-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)piperazine,

1-(2-(7-Bromo-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)piperazine,

1-(2-(4-Chloro-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)piperazine,

1-(2-(6-Trifluoromethyl-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)piperazine,

1-(1H-Indol-4-yl)-4-(2-(5-methyl-1H-indol-3-yl)ethyl)piperazine,

1-(1H-Indol-4-yl)-4-(2-(6-methyl-1H-indol-3-yl)ethyl)piperazine,

1-(1H-Indol-4-yl)-4-(2-(7-methyl-1H-indol-3-yl)ethyl)piperazine,

1-(2-(4,5-Dichloro-3-benzofuranyl)ethyl)-4-(1H-indol-4-yl)piperazine,

1-(2-(5-Bromo-3-benzofuranyl)ethyl)-4-(1H-indol-4-yl)piperazine,

1-(2-(4-Chloro-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)piperidine,

4-(1H-Indol-4-yl)-1-(2-(5-methyl-1H-indol-3-yl)ethyl)piperidine,

4-(1H-Indol-4-yl)-1-(2-(1H-indol-3-yl)ethyl)piperidine,

1-(1H-Indol-4-yl)-4-(3-(4-methyl-3-benzofuranyl)-1-propyl)piperazine,

4-(1H-Indol-4-yl)-1-(3-(4-methyl-3-benzofuranyl)-1-propyl)piperidine,

1-(3-(4-Chloro-3-benzofuranyl)-1-propyl)-4-(1H-indol-4-yl)piperazine,

1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(6-chloro-1H-indol-4-yl)piperazine,

1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(6-fluoro-1H-indol-4-yl)piperazine,

1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(6-cyano-1H-indol-4-yl)piperazine,

1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(7-chloro-1H-indol-4-yl)piperazine,

1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(7-cyano-1H-indol-4-yl)piperazine,

1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(2-cyano-1H-indol-4-yl)piperazine,
1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(1H-indolin-4-yl)piperazine,
1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(1H-indol-6-yl)piperazine and
1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(1H-indol-7-yl)piperazine or a pharmaceutically acceptable acid addition salt thereof.

14. A pharmaceutical composition comprising a compound according to claims 1 to 13 or a pharmaceutically acceptable acid addition salt thereof and at least one pharmaceutically acceptable carrier or diluent.

15. The use of a compound according to claims 1 to 13 or a pharmaceutically acceptable acid addition salt thereof for the preparation of a medicament for the treatment of a disorder or disease responsive to the inhibition of serotonin reuptake and antagonism of 5-HT_{1A} receptors.

16. The use of a compound according to claims 1 to 13 or a pharmaceutically acceptable acid addition salt thereof for the preparation of a medicament for the treatment of affective disorders, such as depression, psychosis, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder.

17. A method for the treatment of a disorder or disease of living animal body, including a human, which is responsive to the inhibition of serotonin reuptake and antagonism of 5-HT_{1A} receptors comprising administering to such a living animal body, including a human, a therapeutically effective amount of a compound according to claims 1 to 13 or a pharmaceutically acceptable acid addition salt thereof.

18. A method for the treatment of an affective disorder, including depression psychosis, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder in a living animal body, including a human, comprising administering a therapeutically effective amount of a compound according to claims 1 to 13 or a pharmaceutically acceptable acid addition salt thereof.